The cellular entry of HIV-1 to CD4 + T-cells requires ordered interactions of HIV-1-26 envelope glycoprotein with CXCR4 receptors. However, such interactions, which should 27 be critical for rational structure-based discovery of new CXCR4 inhibitors, remain poorly 28 understood. Herein, we first determined the effects of amino acid substitutions in CXCR4 29 on HIV-1 NL4-3 -glycoprotein-elicited fusion events using site-directed mutagenesis-based 30 fusion assays and identified eleven potentially key amino acid substitutions, including 31 D97A and E288A, which caused a >30% reduction of the fusion. We subsequently 32 carried out computational search of a screening library containing ~604,000 compounds 33 in order to identify potential CXCR4 inhibitors. The computational search used the shape 34 of IT1t, a known CXCR4 inhibitor, as a reference and employed various algorithms 35 including shape similarity, isomer generation, and docking against a CXCR4 crystal 36 structure. Sixteen small-molecules were identified for biological assays based on their 37 high shape similarity to IT1t and their putative binding modes formed hydrogen bond 38 interactions with amino acids identified above. Three compounds, having a 39 piperidinylethanamine core, showed activity and were resynthesized. One molecule, 40 designated CX6, was proven to significantly inhibit X4-HIV-1 NL4-3 -glycoprotein-elicited 41 fusion (IC 50 : 1.9 µM), inhibit SDF-1α-elicited Ca 2+ flux (IC 50 :92 nM), and exert anti-42 HIV-1 activity (IC 50 :1.5 µM). Structural modeling demonstrated that CX6 bound to 43 CXCR4 through hydrogen-bond interactions with Asp97 and Glu288. Our study suggests 44 that targeting CXCR4 residues important for HIV-1-envelope glycoprotein-elicited fusion 45 should be a useful and practically feasible approach in identifying novel CXCR4 46
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INTRODUCTION 50
Over the last thirty years, the human immunodeficiency virus (HIV-1) has 51 become responsible for more than thirty million deaths worldwide, and approximately 35 52 million people are estimated to be currently infected by the virus (United Nations AIDS 53 cells (2 x 10 5 , 3 ml in 6-well microculture plates) since they do not endogenously express 142 CXCR4. On the next day, both the co-transfected cells were harvested and mixed in a 143 well of 96-well plates (2 x 10 4 cells each). The co-transfected cells were incubated further 144 for 6 hrs and the luciferase activity in each well was detected using Bright-Glo Luciferase 145
Assay System (Promega) and its luminescence level was measured using Veritas 146
Microplate Luminometer (Turner BioSystems, Sunnyvale, CA). Non-specific luciferase 147 activity was determined in the well containing control Tat In brief, the computational search identified potential molecules by the following two 155 simulations: i) initial identification of molecules that had a high shape similarity to IT1t 156 (11), a known CXCR4 inhibitor, and ii) subsequent determination of the putative binding 157 mode and interaction of these molecules to potentially key CXCR4 amino acid residues. 158 A flow diagram of the screening protocol is shown in Fig. 1 . Initially, known aggregators, 159 molecules with more than 20 rotatable bonds or with a molecular weight below 350 160
Dalton and above 750 Dalton were eliminated from consideration. In order to determine 161 the molecules that had a high shape similarity to IT1t, the possible stereoisomers and 162 three dimensional conformations were generated using Omega (version 2.3.2, OpenEye 163 Scientific Software, Inc. Santa Fe, New Mexico), and the shape overlay program ROCS 164 on November 12, 2017 by guest http://aac.asm.org/ Downloaded from (version 3.0.0, OpenEye Scientific Software) was used (20, 21) . The crystal structure 165 conformation of IT1t (11) was used as the query template against which molecules from 166 the chemical database were aligned. Molecules, whose shape similarity Tanimoto 167 coefficient was at least 0.7 with IT1t, were retained for molecular docking. In order to 168 eliminate lack of compatibility between software suites from different sources, the 169 possible ionization states at pH 7±2, tautomers, stereoisomers, and ring conformations of 170 these molecules were again generated (LigPrep version 2.4, Schrödinger, LLC). These 171 structures were docked into CXCR4 using Glide (version 5.6, Schrödinger, LLC) (22, 23) . 172
The crystal water molecules were removed, the docking grid around the binding site of 173
IT1t to CXCR4 was generated, and molecules were docked. Molecules that did not form 174 at least two hydrogen bond interactions with two of the following residues determined to 175 be important for the fusion of gp120-envelope-protein to CXCR4 were eliminated 176 (Asp97, Tyr116, Phe174, Ala175, Asp182, Asp187, Arg188, Tyr190, Asp262, Glu288 177 and Phe292). Selection of the candidate molecules was made by analyzing the putative 178 binding mode and interaction with CXCR4 residues, without explicit consideration of the 179 glide docking scores. 180
Determination of Inhibition of Chemokine Binding to CXCR4. In order to determine 181 if the selected compounds bind to CXCR4, calcium flux binding inhibition assay was 182 conducted using Fluo-4 DirectTM calcium reagent (Invitrogen) according to the 183 manufacturer's protocol. In brief, Molt4 cells (5 x 10 5 cells) were exposed to Fluo-4 184 DirectTM calcium reagent for 60 min at 37ºC in RPMI containing 5% FCS. A test 185 compound was added at various concentrations, incubated for 30 min, and the cells were 186 exposed to stromal cell-derived factor 1 (SDF-1α) at a concentration of 1 nM. Technologies, Inc. Japan) was added to each well in the plate, followed by incubation at 198 37°C for 1-2 hrs and the optical density was measured in a microplate reader suggests that certain transmembrane and extracellular residues are important for gp120 234 binding, and we hypothesized that small molecules that bind to such residues in the 235 orthosteric binding site would likely inhibit the CXCR4-gp120 interactions. To determine 236 these residues, fifty-six amino acid residues in the extracellular and transmembrane 237 regions of CXCR4 were selected for introducing amino acid substitution(s) and the HIV-238 1-gp120-elicited cell fusion levels were determined and compared to that of wild type 239 CXCR4. The intracellular residues are important for signal transduction but do not seem 240 to directly affect anti-HIV-1 inhibitor binding or gp120 fusion; hence they were not 241 considered. The significance of some of the residues selected for substitution are as Cys186 in ECL2. This disulfide linkage is conserved for class-A GPCRs and is known to 251 be important for their structures and functions (11, 31) . The effect on HIV-1 252 glycoprotein-elicited fusion by substitution of some of these residues was reported before 253 (32); however the coverage was partial and we carried out a comprehensive analysis of 254 the effect of CXCR4 amino acid residues on viral induced fusion. 255 substantial reduction in the HIV-1-envelope protein-elicited fusion level by more than 259 30%. Amino acid substitutions C109A, D133A, C186A, and D193A drastically reduced 260 CXCR4-gp120 fusion; however they also had a critical decrease in CXCR4 expression 261 levels on the cell surface as determined by FACS analysis. Thus, we could not conclude 262 if these reductions were because of their functional importance or because of the decrease 263 of expression levels. Substitutions of Asn176 (ECL2) had no effects on the fusion level, 264 in agreement with the data of Brelot et al. (32) . It is noteworthy that there are a number of 265 negatively charged acidic residues (D97A, D182A, D187A, D262A, and E288A) whose 266 substitution significantly decreased gp120 fusion (Fig. 3A) . These acidic residues may 267 interact with the basic residues of gp120 to affect co-receptor selectivity. Negatively 268 charged acidic residues have also been shown to be important for the binding of SDF-1 269 and for CXCR4 co-receptor function in HIV-1 entry (32). 270
We analyzed the crystal structures of CXCR4 (11) have shown that determination of molecular similarity plays a critical role in analyzing 298 large compound databases in chemical and pharmaceutical research (33). Therefore, 299 using the software tool ROCS (21), we determined the shape similarity of the molecules, 300 from the ChemBridge library to IT1t, a molecule that binds with high affinity to CXCR4 301 and demonstrates anti-HIV-1 activity (10, 11). The highest shape similarity Tanimoto 302 coefficient to IT1t from the database was 0.85. Seven-hundred-fifty-three (753) unique 303 molecules with one-thousand-five (1005) configurations/conformations had a shape 304
Tanimoto coefficient of at least 0.70. The binding mode and interactions of these 305 molecules with CXCR4 were determined by molecular docking using Glide (version 5.6, 306
Schrödinger, LLC) (22, 23). To avoid any issues that may arise through using 307 conformations generated by Omega with Glide docking, Ligprep was used to generate 308 molecular configurations and conformations for docking, and it generated fourteen-309 thousand-two-hundred-twenty-six (14,226) of them. These configurations/conformations 310 were docked to the crystal structure of CXCR4 to determine their possible binding modes. 311
Since it had been determined that CXCR4 transmembrane residues Asp97, Tyr116, 312 Asp262, Glu288, Phe292 and ECL2 residues Phe174, Ala175, Asp182, Asp187, Arg188 313 and Tyr190 appeared to be important for the cell fusion event (Fig. 3A) , we hypothesized 314 that molecules that bound around the active site determined in the crystal structure, and 315 formed hydrogen bond interactions with at least two of these residues are likely to 316 competitively inhibit the interactions of CXCR4 with gp120. Our candidate molecule 317 selection was based on shape similarity to a known inhibitor (IT1t) and putative binding 318 on November 12, 2017 by guest http://aac.asm.org/ Downloaded from mode and interactions with residues that were determined to be important for the HIV-1-319 gp120-elicited cell fusion event with CXCR4. Of note, we did not use any energy-based 320 or empirical scoring functions for estimating the relative affinity for the selection of 321 compounds. Based on the hypothesis described above, we selected sixteen compounds 322 (named CX1 to CX16) for biological assays from ChemBridge TM general screening 323 library. Three compounds were piperidinylethanamine derivatives, and four compounds 324
were tetrahydro-β-carboline derivatives. The other compounds had quinoxaline, indole, 325 indane, imidazole, imidazopyridine, imidazothiazole, piperazine, morpholine, and 326 diazepane moieties in them. In computational examination of screening libraries, in some 327 instances completely different cores are selected for assays, but we chose multiple 328 piperidinylethanamine and tetrahydro-β-carboline derivatives as the binding modes were 329 thought to be most substantive. While there are certain advantages to selecting only one 330 compound from one core, we decided not to take that approach because we did not want 331 to eliminate an active core if the only compound we chose happened to be inactive. 332
Inhibition of Chemokine Binding to CXCR4 by Piperidinylethanamine 333
derivatives. We asked whether the sixteen selected compounds bound to CXCR4 by 334 blocking the intracellular Ca 2+ mobilization induced by SDF-1, whose primary receptor 335 is CXCR4. One of the compounds, described as CX6 (Fig. 4) Fig. S1 , 337 supplemental material). In the same assay, AMD3100 showed inhibition of SDF-1-338 induced Ca 2+ mobilization with an IC 50 value of around 10 nM (Fig. S1 , supplemental 339 material). Two other compounds, CX11 and CX13, both piperidinylethanamine (PEA) 340 derivatives like CX6 (Fig. 4) (Fig. S2, supplemental material) CX11, and CX13 were antagonists of CXCR4 (Fig. S3, supplemental material) . In 348 summary, the above data strongly suggest that the PEA derivatives bound to CXCR4 349 with specificity and were antagonists of CXCR4. Subsequently, we newly synthesized 350 CX6 ( Fig. 2 and supplemental material) . Other PEA derivatives in high purity were also 351 synthesized and their characterization is given in the supplemental material. selected through docking simulations suggesting that they bound to a potential orthosteric 357 binding site of CXCR4. These compounds formed hydrogen bonds to at least two amino 358 acid residues most likely to be important for the fusion event, and thereby have the 359 potential to competitively inhibit the fusion event. We thus determined if the compounds 360 were actually able to inhibit the interactions of the HIV-1 NL4-3 envelope protein with 361 CXCR4, and to block the fusion event in the HIV-1-gp120-elicited cell-cell fusion assays 362 with the wild-type CXCR4. Both CX6 and CX11 blocked the fusion with IC 50 values of 363 1.9 µM and 7.9 µM (Table 1) The imidazothiazole ring of IT1t overlays with the cyclopentylpiperidinyl group of CX6. 373
The interactions of the identified hit compound (CX6) with CXCR4 were deduced by 374 molecular docking. The interactions of CX6 with CXCR4 are illustrated in Fig. 5 
B-E. 375
The following amino acid residues of CXCR4 were seen to form the active site (<4Å 376 from the inhibitor) for the binding of CX6: Glu-32 of the N-terminus of CXCR4; Phe-36, 377
Asn-37, Leu-41, and Tyr-45 of TM1; Trp94, Asp97, and Ala98 of TM2; Trp-102 of 378 ECL1; Val-112, His-113, and Tyr-116 of TM3; Cys-186 and Arg-188 of ECL2; and His-379 281, Ile-284, Ser-285, and Glu-288 of TM-7. Thus, the molecule CX6 bound in the 380 active site predominantly formed by residues from transmembranes 1, 2, 3, 7, and ECL2. 381
As expected, no amino acid residues of TM4, TM5, and TM6 had interactions with CX6. 382
The nitrogens of both piperidine groups were determined to be protonated for CXCR4-gp120-elicited fusion. Glu288 is important for the fusion event as it is shown 389 that substitution of Glu288 with alanine results in loss of the CXCR4-gp120-elicited 390 fusion. Sequence alignment indicated that the residue corresponding to Glu288 of 391 CXCR4 is Glu283 of CCR5. Therefore, E283 for CCR5 should be important for the 392 binding of CCR5 antagonist aplaviroc and its analogs, in line with previously published 393 results (18, 29) . Indeed, the substitution of E283 of CCR5 resulted in loss of the CCR5-394 gp120-elicited fusion event, as previously described (18, 29). 395 Both E283 of CCR5 and E288 of CXCR4 represent the 6 th residue of TM7 in both 396 chemokine receptors. Glutamic acid at position 6 in TM7 is a highly conserved amino 397 acid residue in chemokine receptors and has been demonstrated to be important for the 398 binding of non-peptidic ligands to chemokine receptors CCR1 and CCR2 (34). Our 399 current study suggests that Glu288 is an important residue to target for rational structure 400 based design and discovery of CXCR4 inhibitors. 401
Binding of PEA derivatives to CXCR4 and Antiviral Activity against X4-402 HIV-1. Finally, we determined the anti-HIV-1 activity and cytotoxicity of CX6 with the 403 MTT assay using X4-HIV-1 NL4-3 and MT4 as target cells. CX6 suppressed the infectivity 404 and replication of HIV-1 NL4-3 in a good dose-response fashion (Fig. 6) . As shown in 405 (Table 1) . However, as expected, CX6 failed to block 412 the infectivity and replication of an R5-HIV-1 (HIV-1 BaL )(IC 50 : >10 µM) as examined in 413 an anti-HIV assay using HIV-1 BaL and MAGI cells. CX11 and CX13 similarly exerted 414 activity against X4-HIV-1 NL4-3 and X4-HIV-1 LAI , but failed to block the infectivity and 415 replication of R5-HIV-1 BaL (Table 1) . Of note, CX13 was least active among the three 416 PEA derivatives initially examined and only marginally suppressed the fusion event (25 417 to 27% reduction at 10 µM) as examined using the HIV-1 NL-4-3 -derived envelope protein. 418
The cyclopentylpiperidinyl methyl piperidinyl ethylamine (CpPMPEA) is the 419 pharmacophore of these PEA derivatives (Fig. 4) . Substitution of the 420 cyclopentanepiperidinyl group with an m-methoxybenzene moiety abolished activity, 421 confirming that CpPMPEA is critical for the observed activities. 422
After establishing the activity and specificity of the PEA derivatives as described 423 before, we further examined the activity of other PEA derivatives with the CpPMPEA 424 pharmacophore (Fig. 4) . CX20 and CX26 similarly exerted substantial activity against 425 X4-HIV-1 NL4-3 and X4-HIV-1 LAI , but failed to block the infectivity and replication of R5-426 HIV-1 BaL (Fig. 4, Table 1 ). Of note, CX20 exerted the most potent activity against X4-427 HIV-1 NL4-3 and X4-HIV-1 LAI , had a therapeutic index of 67, and most potently inhibited 428 the CXCR4-associated fusion and the SDF-1-induced Ca CX6 an m-phenol). CX26 had comparable anti-HIV-1 activity with an IC 50 value of 2.6 435 µM as compared to CX6, suggesting that the phenol moiety should have good 436 interactions with CXCR4 receptors. We synthesized six other PEA derivatives (CX21, 437 CX22, CX23, CX24, CX25 and CX27) and determined their anti-HIV-1 activities. As 438 assessed in the MTT assay, the compounds had activity against X4-HIV-1 NL4-3 with IC 50 439 values between 0.6 to 2.9 µM (Fig. 4) , further supporting that the CpPMPEA 440 pharmacophore plays significant roles in the interactions and activity of these derivatives 441 with CXCR4. 442 Virtually all inhibitors of CXCR4-gp120 interactions previously reported in the literature 470 were discovered and optimized before the crystal structure became available. The crystal 471 structure reported by Wu et al. (11) , showing an orthosteric binding site, opened up the 472 possibility of discovering novel inhibitor chemotypes and rational optimization of 473 inhibitors. We did a comprehensive examination of the effects of amino acid substitutions 474 in the transmembrane and extracellular domains of CXCR4 on HIV-1-gp120-elicited cell 475 fusion and identified eleven residues important for preserving the interaction of CXCR4 476 with the gp120 protein. We hypothesized that molecules that formed hydrogen bond 477 interactions with at least two of these residues might competitively inhibit the interaction 478 of CXCR4 and gp120 and exert antiviral activity. A general screening library was 479 searched to identify molecules with a high three dimensional shape similarity to a known 480 CXCR4 inhibitor and formed hydrogen bond interactions with at least two of these 481 eleven residues. Using a computational search that took account of the residue-by-residue 482 interaction analysis of CXCR4, we identified piperidinylethanamine derivatives as a 483 novel antagonist family of CXCR4. demonstrate that PEA derivatives exert their activity through strong and specific 490 interaction with CXCR4 and not with CCR5. The current study provides a platform for 491 structure-based discovery of CXCR4 inhibitors. The study also sheds important insight 492 into the mechanism of antiviral activity of inhibitors targeting CXCR4 and our approach 493 may be useful in exploring antagonists against other novel targets by understanding the 494 mechanism of action. 495 TM1 TM2  TM3  TM4  ECL2  TM5  TM6  ECL3  TM7   FIG 3A on November 12, 2017 by guest
